{
  "ticker": "AKRO",
  "company_name": "Akero Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06215716",
      "title": "A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "NASH With Fibrosis, MASH With Fibrosis",
      "start_date": "2023-12-01",
      "completion_date": "2032-11",
      "enrollment": 0,
      "sponsor": "Akero Therapeutics, Inc"
    },
    {
      "nct_id": "NCT03976401",
      "title": "A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "NASH - Nonalcoholic Steatohepatitis",
      "start_date": "2019-05-28",
      "completion_date": "2022-01-10",
      "enrollment": 0,
      "sponsor": "Akero Therapeutics, Inc"
    },
    {
      "nct_id": "NCT04767529",
      "title": "A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "NASH - Nonalcoholic Steatohepatitis",
      "start_date": "2021-02-16",
      "completion_date": "2024-05-02",
      "enrollment": 0,
      "sponsor": "Akero Therapeutics, Inc"
    },
    {
      "nct_id": "NCT05039450",
      "title": "A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "NASH - Nonalcoholic Steatohepatitis",
      "start_date": "2021-07-30",
      "completion_date": "2025-05",
      "enrollment": 0,
      "sponsor": "Akero Therapeutics, Inc"
    },
    {
      "nct_id": "NCT06528314",
      "title": "A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis",
      "start_date": "2024-09-04",
      "completion_date": "2029-10",
      "enrollment": 0,
      "sponsor": "Akero Therapeutics, Inc"
    },
    {
      "nct_id": "NCT06161571",
      "title": "A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "NASH/MASH, NAFLD/MASLD",
      "start_date": "2023-11-10",
      "completion_date": "2026-10",
      "enrollment": 0,
      "sponsor": "Akero Therapeutics, Inc"
    }
  ],
  "summary": {
    "total_trials": 6,
    "by_phase": {
      "PHASE3": 3,
      "PHASE2": 3
    },
    "by_status": {
      "RECRUITING": 2,
      "COMPLETED": 2,
      "ACTIVE_NOT_RECRUITING": 2
    },
    "active_trials": 4,
    "completed_trials": 2,
    "conditions": [
      "NASH - Nonalcoholic Steatohepatitis",
      "NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis",
      "NASH With Fibrosis, MASH With Fibrosis",
      "NASH/MASH, NAFLD/MASLD"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T14:00:05.676621",
    "search_query": "Akero Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Akero+Therapeutics,+Inc."
  }
}